Join to View Full Profile
55 Fruit StYawkey 9ABoston, MA 02114
Phone+1 617-726-6500
Fax+1 617-643-0589
Dr. Isakoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2002
New York University School of MedicineClass of 2000, MD, PhD
Princeton UniversityAB, Molecular Biology, Cum Laude, 1987 - 1991
Certifications & Licensure
MA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response Start of enrollment: 2007 Jun 01
- TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer Start of enrollment: 2008 Aug 01
- ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Publications & Presentations
PubMed
- Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.Yael Bar, Steven J Isakoff, Seth A Wander
JNCI Cancer Spectrum. 2025-09-01 - Selection biases in the systematic collection of breast biobank specimens.Yael Bar, Gary X Wang, Gabrielle E Gioia, Geoffrey Fell, Shinn-Huey S Chou
NPJ Breast Cancer. 2025-08-01 - 11 citationsTOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-05-15
Press Mentions
When to Get First Mammogram? Doctor Explains Latest AdviceMay 12th, 2023- Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-Negative, BRCA-Mutated Breast CancerAugust 10th, 2022
- Ribociclib Dose Modifications Do Not Affect OS in Patients with Hr+/her2 Advanced Breast CancerJune 21st, 2022
Committees
- Breast Cancer Guideline Committee Member, National Comprehensive Cancer Network 2012 - Present
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
